Deelname aan CTMM biedt belangrijke stimulans aan MKB-bedrijven

Deelname aan onderzoeksprojecten van het Center for Translational Molecular Medicine (CTMM) blijkt een belangrijke stimulans te bieden aan MKB-bedrijven.

Eindhoven, 17 december 2012

Dat laat een enquête zien die CTMM onder haar MKB-partners heeft gehouden. Een positieve impact is er onder meer op de omzet, de werknemersgroei en de kwaliteit van de producten.

Voor de komende jaren wordt ook een positief effect verwacht op de winst van de deelnemende MKB-bedrijven.

Daarmee voldoet het publiek-private samenwerkingsverband CTMM aan haar doelstelling om een positieve impact op participerende bedrijven tot stand te brengen en het innovatieve vermogen van Nederland te bevorderen.

Download hier het complete persbericht.

Output boekjes

In het Engels:

If you want to see what 300 million euros of public-private partnership funding can achieve, take a look at the new set of output booklets that have been prepared for the individual CTMM projects.

Scientific breakthroughs, new products, patents, start-up companies, research infrastructures, PhD theses and academic papers, it's all there in black and white - proof that together we have achieved something truly remarkable and placed the Netherlands in a world leading position for translational medical research.

AIRFORCE - personalized chemotherapy against lung cancer

BIOCHIP - Diagnosing leukemia sub-types

Breast CARE - Predicting therapy response in breast cancer patients

DeCoDe - Early diagnosis of colorectal cancer

HIFU-CHEM - More chemo where it should be

MUSIS - Check removal of tumor tissue during surgery

PCMM - Limit over-diagnosis and over-treatment in prostate cancer

VOLTA - Remove tumors through local heating

Circulating Cells - investigating white blood cells and platelets for discriminating patients with increased risk of developing unstable plaques

COHFAR - how to detect and stop ventricular fibrillation by applying a synchronized electrical impulse to heart muscle

Eminence - developing multiple diagnostic technologies to detect neovascularization and stratifying patients

INCOAG - developing a new set of tests to estimate the risk of thrombosis

Parisk - how to predict risk of rupture of an individual plaque

Predicct - focusing on early diagnoses and treatment of Diabetes DM2

Triumph - identifying biomarkers for cardiac failure

LeARN - finding an early diagnosis of Alzheimer's Disease

AmpVacs - a new vaccine technology platform in the combat against conserved influenza A determinants

MARS - tools to provide rapid and accurate information about an individual patient suffering from sepsis

TRACER - patient-tailored treatment of Rheumatoid Arthritis

Health Technology Assessment (HTA)

TraIT - establishing an easy-to-access and easy-to-use infrastructure for sharing of research data, and set of tools for researchers to interact with and explore a unified translational medical research space

March 2018